ISTA positioned itself as a focused ophthalmic specialist with FDA-approved products (BROMDAY, BEPREVE, ISTALOL, VITRASE) and a pipeline targeting ocular inflammation, pain, and glaucoma. The acquisition by Bausch & Lomb was designed to enhance the larger company's pharmaceutical portfolio and expand its ophthalmic pipeline, complementing B+L's existing prescription and OTC eye care products.
Cyborg Score Rationale
ISTA ceased independent operations in June 2012 following its acquisition by Bausch & Lomb. No current business metrics, market position, or strategic posture apply.
Top Insights
Prior to acquisition, ISTA was the fourth-largest branded prescription eye care business in the US
Product portfolio included four key marketed drugs addressing postoperative inflammation, allergic conjunctivitis, glaucoma, and vitreous hemorrhage
Company faced regulatory and legal challenges, including a guilty plea in May 2013 to misbranding and Anti-Kickback Statute violations related to Xibrom marketing
Acquisition integration was seamless into Bausch & Lomb's growing pharmaceutical division, ultimately absorbed into Valeant's portfolio
Named Competitors
Allergan Ophthalmology Products — Ophthalmic pharmaceuticals and botulinum toxin products
Alcon Eye Care Products — Eye care and ophthalmic surgical products